Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection
- Resource Type
- Authors
- Sarah Pickering; Nicolas F. Schlecht; Fanua Wiek; Angela Diaz; Anne Nucci-Sack; Ana Gradissimo; Yevgeniy Y. Studentsov; Viswanathan Shankar; Robert D. Burk; Lauren St Peter
- Source
- Viruses, Vol 13, Iss 1548, p 1548 (2021)
Viruses
Volume 13
Issue 8
- Subject
- HPV16
Adolescent
Sexual Behavior
viruses
Cervix Uteri
Antibodies, Viral
papillomavirus
antibody titer
Microbiology
Article
Immunoglobulin G
quadrivalent vaccine
Serology
Young Adult
Risk Factors
VLP
Virology
Humans
Medicine
Longitudinal Studies
Papillomavirus Vaccines
Prospective Studies
Vaccines, Combined
Longitudinal cohort
Human papillomavirus 16
biology
business.industry
Papillomavirus Infections
Vaccination
Antibody titer
virus diseases
QR1-502
female genital diseases and pregnancy complications
Titer
Infectious Diseases
Quartile
Case-Control Studies
Immunology
biology.protein
Female
Antibody
business
- Language
- ISSN
- 1999-4915
The goal of this study was to investigate the serological titers of circulating antibodies against human papillomavirus (HPV) type 16 (anti-HPV16) prior to the detection of an incident HPV16 or HPV31 infection amongst vaccinated participants. Patients were selected from a prospective post-HPV vaccine longitudinal cohort at Mount Sinai Adolescent Health Center in Manhattan, NY. We performed a nested case–control study of 43 cases with incident detection of cervical HPV16 (n = 26) or HPV31 (n = 17) DNA who had completed the full set of immunizations of the quadrivalent HPV vaccine (4vHPV). Two control individuals whom had received three doses of the vaccine (HPV16/31-negative) were selected per case, matched on age at the first dose of vaccination and follow-up time in the study: a random control, and a high-risk control that was in the upper quartile of a sexual risk behavior score. We conducted an enzyme-linked immunosorbent assay (ELISA) for the detection of immunoglobulin G (IgG) antibodies specific to anti-HPV16 virus-like particles (VLPs). The results suggest that the average log antibody titers were higher among high-risk controls than the HPV16/31 incident cases and the randomly selected controls. We show a prospective association between anti-HPV16 VLP titers and the acquisition of an HPV16/31 incident infection post-receiving three doses of 4vHPV vaccine.